Status:
COMPLETED
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Lead Sponsor:
Johann Wolfgang Goethe University Hospital
Conditions:
Differences in Laboratory Coagulation Parameters
Eligibility:
All Genders
18+ years
Brief Summary
Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedi...
Detailed Description
To validate the effects of Rivaroxaban on coagulation parameters plasma samples of patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d are investigated. Plasma samples are...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d
- must be able to accept blood sampling
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2011
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00986635
Start Date
September 1 2009
End Date
April 1 2011
Last Update
April 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Frankfurt
Frankfurt am Main, Germany, 60590